Knowledge Graph · Condition
Type 2 Diabetes
A chronic condition affecting how the body metabolizes glucose.
Authoritative sources
Evidence base
Randomized Controlled Trial · 2025
Cagrilintide-Semaglutide in Adults with Overweight or Obesity and Type 2 Diabetes
The New England journal of medicine · Davies MJ, Bajaj HS, Broholm C, Eliasen A, et al.
Phase III Clinical Trial · 2025
Cardiovascular Outcomes with Tirzepatide versus Dulaglutide in Type 2 Diabetes
The New England journal of medicine · Nicholls SJ, Pavo I, Bhatt DL, Buse JB, et al.
Randomized Controlled Trial · 2025
Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist, in Early Type 2 Diabetes
The New England journal of medicine · Rosenstock J, Hsia S, Nevarez Ruiz L, Eyde S, et al.
Randomized Controlled Trial · 2025
Lancet (London, England) · Bonaca MP, Catarig AM, Houlind K, Ludvik B, et al.
Meta-Analysis · 2024
Phytotherapy research : PTR · Moridpour AH, Kavyani Z, Khosravi S, Farmani E, et al.
Meta-Analysis · 2024
The Journal of clinical endocrinology and metabolism · Uhl S, Choure A, Rouse B, Loblack A, et al.
Randomized Controlled Trial · 2022
European heart journal · Agarwal R, Filippatos G, Pitt B, Anker SD, et al.
Randomized Controlled Trial · 2021
Lancet (London, England) · Davies M, Færch L, Jeppesen OK, Pakseresht A, et al.
Randomized Controlled Trial · 2021
Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes
The New England journal of medicine · Frías JP, Davies MJ, Rosenstock J, Pérez Manghi FC, et al.
Randomized Controlled Trial · 2021
Cardiovascular Events with Finerenone in Kidney Disease and Type 2 Diabetes
The New England journal of medicine · Pitt B, Filippatos G, Agarwal R, Anker SD, et al.
Where Type 2 Diabetes appears on Kindr Health
Data hub
Wiki
This page is part of Kindr Health's public Knowledge Graph. Content is for educational purposes only and is not medical advice.